Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors

An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors

This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 for Injection (Subcutaneous) in participants with advanced solid tumors.

Study Overview

• Status: Not yet recruiting
• Conditions: Efficacy; Tolerability; Safety
• Intervention / Treatment: Drug: Test Product HY07121 for Injection (Subcutaneous); Drug: Test Product HY07121 for Injection (Subcutaneous)

Detailed Description

The study starts with a dose escalation part (Part 1) followed by a dose expansion part (Part 2). The main purpose of this study is to evaluate the safety and tolerability of the drug HY07121 for Injection (Subcutaneous) and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) and preliminary anti-tumor activity. Additional purposes of the study are to evaluate the pharmacokinetics (PK) properties, immunogenicity, correlation of the biomarkers and PK profile with anti-tumor activity.

• Study Type: Interventional
• Enrollment (Estimated): 254
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Jinmin Yu, Doctor; Phone Number: +86-521-67626971; Email: sdyujinming@126.com
• Study Contact Backup: Name: Hongxu Liu, Doctor; Phone Number: +86-024-81916200; Email: liuhongxu3366@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Written informed consent;
• ≥18 years old and ≤80 years old, gender: male or female;
• Dose escalation part: cytologically or histopathologically confirmed locally advanced or advanced solid tumor that has failed standard therapy, or for which no standard therapy exists, or for which standard therapy is not tolerated or has been refused (for tumor types for which PD-1/PD-L1-related inhibitors are approved in China, failure of prior PD-1/PD-L1-related inhibitor therapy is required). Solid tumors in the dose expansion part include non-small cell lung cancer (driver gene-negative), gastric cancer, esophageal cancer, Microsatellite Instability-High / Mismatch Repair-Deficient Solid Tumors (MSI-H/dMMR) solid tumors, cervical cancer, non-muscle-invasive bladder cancer, head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma), renal cell carcinoma, and other tumor types;
• Dose escalation part: at least one evaluable tumor lesion is required. Dose expansion part: at least one measurable tumor lesion is required (per RECIST v1.1);
• Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;
• Life expectancy ≥3 months;
• Participant must have adequate main organ function;
• Fertile female patients must have a negative serological pregnancy test within 7 days before the first dosing and be willing to use effective birth control/contraception to prevent pregnancy during the study period up to 6 months after the last dosing of the study. Male patients must agree to have no sperm donation plans and to use effective contraceptive methods during the study period until 6 months after the last dose of the study.
• Postmenopausal women must have amenorrhea for at least 12 months before they are considered infertile.

Exclusion Criteria:

• Within the defined washout periods for prior anti-cancer treatments;
• Participant is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of HY07121.
• Any other malignancy within 2 years prior to the first dose of the study treatment except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence.
• Participant has not recovered (i.e., to Grade 1 or to baseline) from previous anticancer therapy-induced Adverse Events (AEs).
• Participants with a history of recently (within previous 2 years of the first dose of the study treatment) active diverticulitis or symptomatic peptic ulcer disease;
• Major surgery within 4 weeks of receiving the first dose of study treatment;
• Participant has Symptomatic Central Nervous System (CNS) metastases, or CNS metastases requiring CNS-directed local therapy (such as radiotherapy or surgery) or corticosteroids therapy within 4 weeks of first dose of study treatment;
• Participants with untreated or under treatment for tuberculosis, including but not limited to tuberculosis; Patients who have received standardized anti-tuberculosis treatment and have been confirmed cured by the researchers can be included;
• Participants with clinically significant cardiovascular diseases, in the past 6 months prior to the first dose of the study treatment; symptomatic coronary heart disease requiring drug treatment; arrhythmia requiring drug treatment; or uncontrolled hypertension;
• Known Human Immunodeficiency Virus (HIV) infection or known Acquired Immunodeficiency Syndrome (AIDS);
• Active or chronic hepatitis B or hepatitis C infection; treponema pallidum antibody positive, and confirmed positive test;
• Active known or suspected autoimmune disease.
• History of non-infectious pneumonitis that has required a course of oral or intravenous steroids to assist with recovery, or interstitial lung disease or severe obstructive pulmonary disease;
• History of severe allergy;
• History of allogeneic organ transplantation or graft-versus-host disease;
• Have received live/attenuated vaccines and messenger ribonucleic acid(mRNA) vaccines within 4 weeks prior to screening or plan to receive live/attenuated vaccines and mRNA vaccines during the study period;
• Any active infection requires systemic treatment via intravenous infusion within 4 weeks prior to the first dose of study treatment;
• Known psychiatric disorder or drug abuse that would interfere the trial requirements;
• Participant with uncontrolled pleural effusion, pericardial effusion or peritoneal effusion or need drainage;
• In addition to the tumors present at the time of entry into the study, other active malignancies were present within 3 years prior to the first dose (not excluding locally cured tumors, such as skin basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the breast, etc.);
• Participants considered unsuitable for participation in this study by the investigators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: : Test product HY07121 for Injection (Subcutaneous) for Dose Escalation; PART ONE- Dose escalation: HY07121 for Injection (Subcutaneous) should be administered Subcutaneously at recommended dose. The purpose of the Dose Escalation Phase (Part one) is to characterize the safety and tolerability of the test product HY07121 for Injection (Subcutaneous) and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) based on the frequency of the occurrence of Dose-Limiting Toxicity (DLT) in each cohort during the DLT evaluation period.	Drug: Test Product HY07121 for Injection (Subcutaneous); Dosage form: Powder for solution for infusion. Strength: 10 mg/vial. Method of administration: Subcutaneous administration. Dose escalation: "3+3" dose escalation rules are used to explore the safety and tolerability of the drug HY07121 for Injection (Subcutaneous).Based on emerging clinical data, dose escalation of an SUD-containing regimen may also follow a standard "3+3" design. Dose expansion: according to the preliminary safety and efficacy results of the dose escalation study, an appropriate dose and tumor species for the expansion study are conducted as discussed by the sponsor and investigators to further explore the safety and clinical effectiveness of the drug product HY07121 for Injection (Subcutaneous) and provide a basis for subsequent clinical studies.; Other Names: HY0007-SC-101; Drug: Test Product HY07121 for Injection (Subcutaneous); Dosage form: Powder for solution for infusion. Strength: 10 mg/vial. Method of administration: I Subcutaneous administration. Dose escalation: "3+3" dose escalation rules are used to explore the safety and tolerability of the drug HY07121 for Injection (Subcutaneous).Based on emerging clinical data, dose escalation of an SUD-containing regimen may also follow a standard "3+3" design. Dose expansion: according to the preliminary safety and efficacy results of the dose escalation study, an appropriate dose and tumor species for the expansion study are conducted as discussed by the sponsor and investigators to further explore the safety and clinical effectiveness of the drug product HY07121 for Injection (Subcutaneous) and provide a basis for subsequent clinical studies.; Other Names: HY0007-SC-101
Experimental: Test product HY07121 for Injection (Subcutaneous) for Dose Expansion; PART TWO- Dose expansion: HY07121 for Injection (Subcutaneous) should be administered Subcutaneously at recommended dose. Patients will be administered a recommended dose of HY07121 for Injection (Subcutaneous) established from the Dose Escalation Phase of the study.	Drug: Test Product HY07121 for Injection (Subcutaneous); Dosage form: Powder for solution for infusion. Strength: 10 mg/vial. Method of administration: Subcutaneous administration. Dose escalation: "3+3" dose escalation rules are used to explore the safety and tolerability of the drug HY07121 for Injection (Subcutaneous).Based on emerging clinical data, dose escalation of an SUD-containing regimen may also follow a standard "3+3" design. Dose expansion: according to the preliminary safety and efficacy results of the dose escalation study, an appropriate dose and tumor species for the expansion study are conducted as discussed by the sponsor and investigators to further explore the safety and clinical effectiveness of the drug product HY07121 for Injection (Subcutaneous) and provide a basis for subsequent clinical studies.; Other Names: HY0007-SC-101; Drug: Test Product HY07121 for Injection (Subcutaneous); Dosage form: Powder for solution for infusion. Strength: 10 mg/vial. Method of administration: I Subcutaneous administration. Dose escalation: "3+3" dose escalation rules are used to explore the safety and tolerability of the drug HY07121 for Injection (Subcutaneous).Based on emerging clinical data, dose escalation of an SUD-containing regimen may also follow a standard "3+3" design. Dose expansion: according to the preliminary safety and efficacy results of the dose escalation study, an appropriate dose and tumor species for the expansion study are conducted as discussed by the sponsor and investigators to further explore the safety and clinical effectiveness of the drug product HY07121 for Injection (Subcutaneous) and provide a basis for subsequent clinical studies.; Other Names: HY0007-SC-101

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Escalation (Part One): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)	Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading	Up to 2 years
Dose Escalation (Part One): Percentage of participants experiencing Adverse Event (AE) related dose interruptions, dose delays, and dose intensity	Occurrence of Adverse Event (AE) related dose interruptions, dose delays and dose intensity (duration of HY07121 exposure)	Up to 2 years
Dose Expansion (Part Two): Objective Response Rate (ORR)	Proportion of participants who have a confirmed Complete Response (CR) or a Partial Response (PR)	Up to 2 years
Dose Escalation (Part One): Incidence and Nature of Dose-Limiting Toxicity (DLT)	Dose-Limiting Toxicity (DLT) will be defined using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	28 days during the first 4-week cycle

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Expansion (Part Two): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)	Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading	Up to 2 years
Dose Expansion (Part Two): Percentage of participants experiencing adverse event (AE) related dose interruptions, dose delays, and dose intensity	Occurrence of adverse event (AE) related dose interruptions, dose delays and dose intensity (duration of HY07121 exposure).	Up to 2 years
Dose Escalation and Expansion: Assessment of HY07121 Cmax	Maximum concentration observed (Cmax) observed from the pharmacokinetic profile	Up to 2 years
Dose Escalation and Expansion: Assessment of HY07121 AUC	Area under the concentration versus time curve calculated using the trapezoidal method	Up to 2 years
Dose Escalation and Expansion: Assessment of HY07121 T1/2	The time it takes for half the drug concentration to be eliminated calculated using slope of the terminal line	Up to 2 years
Dose Escalation and Expansion: Assessment of HY07121 anti-drug-antibody (ADA)	Incidence, duration, titer of serum anti-HY07121 antibody (ADA)	Up to 2 years
Dose Escalation (Part One): Objective Response Rate (ORR)	Proportion of participants who have a confirmed complete response (CR) or a Partial Response (PR) determined by Investigator per the Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1	Up to 2 years
Dose Escalation and Expansion: Duration Of Response (DOR) assessed by investigator per Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1	Duration Of Response (DOR) is defined as the time from the measurement criteria are first met for complete response (CR) /Partial Response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease.	Up to 2 years
Dose Escalation and Expansion: Disease Control Rate (DCR) assessed by investigator per RECIST Version 1.1	Disease Control Rate is defined as the percentage of participants who have achieved CR or PR or have demonstrated stable disease	Up to 2 years
Dose Escalation and Expansion: The correlation between tumor biomarkers and efficacy	Objective Response Rate (ORR) is defined as proportion of participants who have a confirmed Complete Response (CR) or a Partial Response (PR) determined by Investigator per RECIST version 1.1. Tumor biomarkers will be tested using Immunohistochemistry (IHC) and scored using Tumor Proportion Score (TPS) and/or Combined Positive Score (CPS) algorithm.	Up to 2 years
Dose Escalation and Expansion: Progression-Free Survival (PFS) assessed by investigator per RECIST Version 1.1	Progression-Free Survival (PFS) is defined as the time from the date of first administration of HY07121 for Injection (Subcutaneous) to the date of the first documented disease progression determined by Investigator as per RECIST 1.1 or death from any cause, whichever occurs first	Up to 2 years
Dose Escalation and Expansion: Time-To-Progression (TTP) assessed by investigator per RECIST Version 1.1	Time-To-Progression (TTP) is defined as the time from the date of first administration of HY07121 for Injection (Subcutaneous) to the date of the first documented disease progression	Up to 2 years
Dose Escalation and Expansion: Overall Survival (OS)	Overall Survival (OS) is defined as the time from the date of first administration of HY07121 for Injection (Subcutaneous) to death due to any cause	Up to 2 years

Collaborators and Investigators

• Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Study record dates

Study Major Dates

• Study Start (Estimated): September 8, 2026
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): October 1, 2028

Study Registration Dates

• First Submitted: August 24, 2026
• First Submitted That Met QC Criteria: August 24, 2026
• First Posted (Actual): August 27, 2026

Study Record Updates

• Last Update Posted (Actual): August 27, 2026
• Last Update Submitted That Met QC Criteria: August 24, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Therapeutics; Drug Administration Routes; Drug Therapy; Injections; Injections, Subcutaneous
• Other Study ID Numbers: HY0007-SC-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No